Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Liminal BioSciences Inc. LMNL

Liminal BioSciences is a biopharmaceutical company focused on the discovery and development of novel, small molecule drug candidates for the treatment of patients suffering from fibrotic or inflammatory diseases that have a high unmet medical need. Liminal BioSciences operates on an integrated basis from our talent hubs in Laval, Quebec, Canada, and Cambridge, UK. Our common shares are listed for trading on the Nasdaq Global Market.


NDAQ:LMNL - Post by User

Bullboard Posts
Post by ualcin1on Feb 01, 2019 10:06am
277 Views
Post# 29305333

A year ago today,

A year ago today,

PLI's SP began its long descent into hell.  On that day, the stock had reached $1.80 and a week later, it was trading at $1.45. Then, towards the end of March, as rumours of an unfavourable FDA decision began to circulate, PLI's share price began to collapse to crash to $0.63 on April 4, 2018. We then learned that Mr. Laurin had not seen fit to retain the services of expert FDA consultants to process his application for approval with the FDA.

Currently, the shares fluctuate between 29 and 30 cents...

Bullboard Posts